کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
1426001 986789 2010 8 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Nanoparticle–integrin antagonist C16Y peptide treatment of choroidal neovascularization in rats
موضوعات مرتبط
مهندسی و علوم پایه مهندسی مواد بیومتریال
پیش نمایش صفحه اول مقاله
Nanoparticle–integrin antagonist C16Y peptide treatment of choroidal neovascularization in rats
چکیده انگلیسی

Choroidal neovascularization (CNV) is the major cause of severe vision loss in patients with age-related macular degeneration (AMD). Present drug delivery may be limited by poor delivery to the choroid where CNV originates. The goal of this study was to develop a drug delivery system to deliver an integrin–antagonist peptide to the sub-retinal space. We developed polylactic acid/polylactic acid–polyethylene oxide nanoparticles (PLA/PLA-PEO) encapsulating the water-soluble integrin–antagonist peptide, C16Y (C16Y-NP). The PLA/PLA-PEO nanoparticles were 302 +/− 85.1 nm in size and demonstrated a two-week sustained release, in vitro, of encapsulated C16Y. Injected nanoparticles did not demonstrate retinal toxicity as determined by histopathology. C16Y peptide solution or C16Y-NP was injected 5 or 9 days post laser photocoagulation. A single intravitreal injection of C16Y peptide and C16Y-NP solution at both 5 days and 9 days post laser photocoagulation statistically inhibited CNV (p < 0.05). However, for the day 5 injections the area of choroidal neovascularization on day 12 was smaller for C16Y-NP than for C16Y peptide solution (p < 0.05) because of the short vitreous half-life of C16Y peptide solution. These results demonstrate the importance of sustained release delivery for the treatment of choroidal neovascularization associated with age-related macular degeneration. The intravitreally administered PLA/PLA-PEO containing coumarin was found to penetrate the retina and localize to the RPE. These results suggest that nanoparticles of biodegradable polymers may be a potential useful delivery system for intravitreal injection of drugs in the treatment of AMD.

A single intravitreal injection of C16Y peptide and C16Y-NP solution at 5 days post laser photocoagulation statistically inhibited CNV (p < 0.05). However, C16Y-NP solution on day 5 reduced the area of choroidal neovascularization more than the C16Y peptide solution on day 5 (p < 0.05) because of the short vitreous half-life of C16Y peptide solution. These results demonstrate the importance of sustained release delivery for the treatment of choroidal neovascularization associated with age-related macular degeneration.Figure optionsDownload as PowerPoint slide

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Controlled Release - Volume 142, Issue 2, 3 March 2010, Pages 286–293
نویسندگان
, ,